ENZON PHARM (EZ1.SG)
Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon… Read more
ENZON PHARM (EZ1.SG) (EZ1) - Total Assets
Latest total assets as of September 2025: €43.69 Million EUR
Based on the latest financial reports, ENZON PHARM (EZ1.SG) (EZ1) holds total assets worth €43.69 Million EUR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ENZON PHARM (EZ1.SG) - Total Assets Trend (2016–2024)
This chart illustrates how ENZON PHARM (EZ1.SG)’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
ENZON PHARM (EZ1.SG) - Asset Composition Analysis
Current Asset Composition (December 2024)
ENZON PHARM (EZ1.SG)'s total assets of €43.69 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 99.3% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how ENZON PHARM (EZ1.SG)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ENZON PHARM (EZ1.SG)'s current assets represent 100.0% of total assets in 2024, an increase from 70.2% in 2016.
- Cash Position: Cash and equivalents constituted 99.3% of total assets in 2024, up from 67.8% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
ENZON PHARM (EZ1.SG) Competitors by Total Assets
Key competitors of ENZON PHARM (EZ1.SG) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
ENZON PHARM (EZ1.SG) - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - ENZON PHARM (EZ1.SG) generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, ENZON PHARM (EZ1.SG) generates $ 1.65 in net profit.
ENZON PHARM (EZ1.SG) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 80.86 | 107.24 | 117.07 |
| Quick Ratio | 80.86 | 107.24 | 117.07 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €43.13 Million | € 46.53 Million | € 47.82 Million |
ENZON PHARM (EZ1.SG) - Advanced Valuation Insights
This section examines the relationship between ENZON PHARM (EZ1.SG)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.78 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -1.1% |
| Total Assets | €47.17 Million |
| Market Capitalization | $1.47 Million USD |
Valuation Analysis
Below Book Valuation: The market values ENZON PHARM (EZ1.SG)'s assets below their book value (0.03 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: ENZON PHARM (EZ1.SG)'s assets decreased by 1.1% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for ENZON PHARM (EZ1.SG) (2016–2024)
The table below shows the annual total assets of ENZON PHARM (EZ1.SG) from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €47.17 Million | -1.12% |
| 2023-12-31 | €47.70 Million | +0.24% |
| 2022-12-31 | €47.59 Million | -0.35% |
| 2021-12-31 | €47.75 Million | -0.99% |
| 2020-12-31 | €48.23 Million | +644.55% |
| 2019-12-31 | €6.48 Million | -58.23% |
| 2018-12-31 | €15.51 Million | +63.06% |
| 2017-12-31 | €9.51 Million | -15.61% |
| 2016-12-31 | €11.27 Million | -- |